In May 2019, ACCC and SITC hosted a by-invitation Joint Immuno-Oncology Policy Summit in Washington, D.C. The interdisciplinary discussion focused on next steps in advancing immunotherapy for cancer with a focus on three areas: telehealth, CAR T implications, and care coordination and workforce issues. In this video, summit participants Sarah Murawski, MPAS, PA-C, Hematology/Oncology, Stem Cell Transplant, Cellular Therapy Nocturnist, Vanderbilt Ingram Cancer Center, and Robert Richards, MBA, Administrative Director, Cell Therapy and Transplant, Penn Medicine, UPenn Health System, talk about the future of CAR-T therapy, the need for adequate reimbursement for CAR T, and the potential role telehealth may play in expanding access to this promising new therapy.
![[Publication] Immuno-Oncology in 2020: What We’ve Learned and What Lies Ahead](https://cdn.sanity.io/images/0vv8moc6/accc-cancer/bfe59825abe0dd1669260c33c2931629f9328774-258x333.png)
This new white paper explores the most recent ACCC resources to meet the evolving needs of the multidisciplinary care team and describes next steps for supporting optimal IO care delivery.
As immune checkpoint inhibitors have become the standard of care for eligible patients with NSCLC, frequent monitoring of irAEs as well as provider and patient education on the signs and symptoms of pneumonitis can ensure improved clinical outcomes for patients.
June is Cancer Immunotherapy Month, and ACCC is highlighting the important work that it and its partners are doing to increase patient access to these novel therapies.
Explore strategies to improve communication, build trust, and improve relationships between clinicians and administrators, ensuring the creation of safe and supportive environments for both team members and patients.
After realizing that a growing number of patients with cancer experienced significant delays and denials in home care and hospice services, Shaw Cancer Center built an oncology-specific home- and community-based palliative care program from the ground up.
Explore the current landscape, unique challenges, emerging trends, and strategic considerations for women’s oncology, and understand the importance of coordinated, multidisciplinary care models.
This article explores the exciting potential for pharmacists in the cardio-oncology setting, where their knowledge of oncolytic therapies, drug interactions, and toxicity management proves integral to patient care.